Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction (HFrEF)

Indications & Patient Selection

• The American College of Cardiology (ACC) recommends replacing ACE inhibitors or ARBs with sacubitril/valsartan in all adults with chronic HFrEF (LVEF ≤ 40%) and NYHA class II–IV symptoms, because this strategy reduces cardiovascular death and HF hospitalization by ≈ 20% versus enalapril. Class I, strong evidence 1, 2
• Eligible patients must have a left ventricular ejection fraction ≤ 40% [Class I] 1, 2
• NYHA functional class II–IV symptoms are required (class II–III most studied; limited data for class IV) [Class I] 1, 2
• Patients should be currently tolerating an ACE inhibitor or ARB, although ACE/ARB‑naïve individuals may start sacubitril/valsartan directly [Class I] 2
• Baseline systolic blood pressure must be ≥ 100 mm Hg [Class I] 3
• Baseline estimated glomerular filtration rate must be ≥ 30 mL/min/1.73 m² [Class I] 3
• Baseline serum potassium must be ≤ 5.2 mmol/L [Class I] 3
• A prior history of angioedema with ACE‑inhibitor or ARB therapy excludes use of sacubitril/valsartan [Class I] 2

Transitioning from Existing Therapy

• From ACE inhibitors: A mandatory 36‑hour washout after the last ACE‑inhibitor dose is required before initiating sacubitril/valsartan to prevent angioedema; concurrent use is an absolute contraindication. Class I, strong evidence 1, 2
• From ARBs: No washout period is needed; patients can switch directly to sacubitril/valsartan. Class I 1, 2
• De‑novo (ACE/ARB‑naïve) initiation: Direct start is safe and effective, especially in hospitalized patients with acute decompensated HF after hemodynamic stabilization. Class I 2

Dosing & Titration

• Standard starting dose: 49/51 mg orally twice daily for most patients. [Class IIa] 4
• Reduced starting dose (24/26 mg BID): Recommended for patients with severe renal impairment, moderate hepatic impairment (Child‑Pugh B), age ≥ 75 years, or baseline SBP 100–110 mm Hg. [Class IIa] 4
• Titration: Double the dose every 2–4 weeks as tolerated. [Class IIa] 2, 4
• Target maintenance dose: 97/103 mg twice daily. [Class IIa] 1, 4
• Minimum effective dose: 49/51 mg twice daily (≥ 50 % of target dose meets quality‑metric criteria). [Class IIa] 4

Monitoring Requirements

• Within 1–2 weeks of initiation or any dose increase, check blood pressure, serum creatinine/eGFR, and serum potassium to detect hypotension, renal dysfunction, or hyper‑kalemia. [Class I] 1
• Ongoing assessments of blood pressure, renal function, electrolytes, and HF symptoms (functional capacity, quality of life) at each titration step. [Class I] 1

Management of Common Adverse Effects

• Hyperkalemia: Occurs more frequently when sacubitril/valsartan is combined with a mineralocorticoid receptor antagonist (MRA). Manage with dietary potassium restriction, potassium‑binding agents, or MRA dose reduction. [Class IIa] 1, 2
• Worsening renal function: Less common than with enalapril in the PARADIGM‑HF trial; symptomatic hypotension with sacubitril/valsartan was not associated with renal decline. [Class IIa] 1
• Angioedema: Numerically higher incidence than enalapril but not statistically different; any history of angioedema with prior ACE‑inhibitor or ARB is an absolute contraindication. [Class III harm] 1, 2

Contraindications

• Concomitant use with ACE inhibitors (absolute contraindication; Class III, harmful) 2
• History of angioedema related to prior ACE‑inhibitor or ARB therapy (Class III, harmful) 2

Clinical Pitfalls & Practical Tips

• Do not delay initiation awaiting addition of an MRA; sacubitril/valsartan can be started without a prior aldosterone antagonist. [Class I] 1
• Do not withhold therapy in patients with borderline SBP (100–110 mm Hg); start at the reduced dose and monitor closely. (Supported by dosing guidance) [Class IIa] 4
• Do not accept sub‑target dosing; aim for the full target dose (97/103 mg BID) or at least 50 % of target (49/51 mg BID) because a dose‑response relationship improves outcomes. [Class IIa] 4
• Never omit the 36‑hour ACE‑inhibitor washout; this step is critical to prevent life‑threatening angioedema. [Class I] 1, 2

Sacubitril/Valsartan Treatment for Heart Failure

Indications and Patient Selection

• The American College of Cardiology recommends sacubitril/valsartan as a replacement for ACE inhibitors or ARBs in patients with symptomatic heart failure with reduced ejection fraction to reduce morbidity and mortality 5
• Direct initiation of sacubitril/valsartan without prior ACE inhibitor or ARB exposure is safe and effective, according to the American College of Cardiology 5

Important Considerations Before Initiation

• The American College of Cardiology advises ensuring patients are not volume-depleted at the time of initiation to avoid hypotension 5
• In patients with borderline blood pressure, careful administration and follow-up are advised by the American College of Cardiology 5

Managing Potential Side Effects

• Hypotension is the most common side effect, with 16.0% of patients experiencing asymptomatic hypotension and 11.1% experiencing symptomatic hypotension in the PARADIGM-HF trial 6
• The European Journal of Heart Failure notes that despite hypotension, the efficacy and safety of sacubitril/valsartan are maintained 6
• In patients with borderline blood pressure, the American College of Cardiology suggests reducing loop diuretic doses in non-congested patients to mitigate hypotensive effects 5

Special Considerations

• The American College of Cardiology states that initiating sacubitril/valsartan during hospitalization for acute decompensated heart failure is feasible after hemodynamic stabilization 5
• About 25% of patients may develop hypotension when treated with sacubitril/valsartan in the hospital setting, according to the American College of Cardiology 5
• The European Journal of Heart Failure notes that benefits of sacubitril/valsartan are consistent across all baseline systolic blood pressure categories, including <110 mmHg 6

Monitoring and Follow-up

• The American College of Cardiology recommends close follow-up and serial assessments after initiation, including blood pressure, electrolytes, and renal function 5
• The European Journal of Heart Failure and the American College of Cardiology advise monitoring for symptomatic hypotension, especially in patients with borderline blood pressure 5, 6

Angiotensin System Inhibitors and Mineralocorticoid Receptor Antagonists for Heart Failure with Reduced Ejection Fraction

Introduction to Angiotensin System Inhibitors

• The American College of Cardiology recommends the use of angiotensin system inhibitors, including ACE inhibitors, ARBs, and ARNI (sacubitril/valsartan), for the treatment of heart failure with reduced ejection fraction (HFrEF) 7, 8

Angiotensin System Inhibitors

• The European Heart Journal recommends the use of ACE inhibitors, such as captopril, enalapril, lisinopril, ramipril, and trandolapril, for the treatment of HFrEF 8
• The European Heart Journal also recommends the use of ARBs, such as candesartan, valsartan, and losartan, as alternatives to ACE inhibitors for patients with HFrEF 8
• Sacubitril/valsartan (ARNI) is preferred over ACE inhibitors/ARBs for patients with HFrEF who remain symptomatic despite optimal treatment, and reduces cardiovascular mortality by 20% compared to enalapril 7, 9, 10, 11

Mineralocorticoid Receptor Antagonists

• The European Heart Journal recommends the use of mineralocorticoid receptor antagonists (MRAs), such as spironolactone and eplerenone, for the treatment of symptomatic HFrEF patients 8
• MRAs reduce mortality and hospitalization in symptomatic HFrEF patients 8, 12

Clinical Benefits

• ACE inhibitors reduce morbidity and mortality in patients with mild, moderate, or severe HF symptoms, according to the American College of Cardiology 7
• ARBs are alternatives for ACE inhibitor-intolerant patients, as stated by the American College of Cardiology 7
• ARNI (sacubitril/valsartan) provides superior reduction in cardiovascular death and HF hospitalization compared to ACE inhibitors, as recommended by the American College of Cardiology 7